Search Results - "Pujana, M.A."

175 Identification of Inhibitors with Specificity for Breast Cancer Cells with Acquired Resistance to Endocrine Treatment by Aguilar, H, Halonen, P, Serra-Musach, J, Rodríguez-Vida, A, Tirado, O.M, Beijersbergen, R.L, Urruticoechea, A, Pujana, M.A

Get full text

578 TGFB2 and NTF3 stromal chemokines that correlate with colorectal cancer progression by Berdiel, M, Cuadras, D, Puertas, S, Salazar, R, Pujana, M.A, Villanueva, A, Molleví, D.G

Get full text

PD-0825 A transcriptomic biomarker predicts response to genotoxic cancer therapy by Guix, I., Lazar, A., Mao, J., Pujana, M.A., Barcellos-Hoff, M.H.

Get full text

Mechanism based signatures of TGFβ competency and DNA repair predict response to genotoxic therapies across cancer types by Barcellos-Hoff, M., Sauquet, I. Guix, Moore, J., Pujana, M.A.

Get full text

497 Liver microenvironment stimulates aggressiveness of colorectal tumour cells more efficiently than matched primary tumour microenvironment – Hepatic CAFs induce ERK-mediated modification of cell morphology by Berdiel, M, López-Doriga, A, Puertas, S, Aytes, A, Colomé, N, Canals, F, Salazar, R, Pujana, M.A, Villanueva, A, Molleví, D.G

Get full text

Epigenetic mechanisms and therapeutic opportunities in metastatic castration resistant prostate cancer by Ruggero, K, Giacobbe, A, Mitrofanova, A, Calvet, A, Palomero, L, Pujana, M.A, Califano, A, Abate-Shen, C, Aytes, A

Get full text

The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent by Ruggero, K., Martinez, A., Chen, X., Bizri, R El, Farran, S., Palomero, L., Piulats, J.M., Villanueva, A., Pujana, M.A., Aytes, A.

Get full text

2013P - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent by Ruggero, K., Martinez, A., Chen, X., Bizri, R El, Farran, S., Palomero, L., Piulats, J.M., Villanueva, A., Pujana, M.A., Aytes, A.

“…Resistance to androgen receptor signaling is arguably the principal hallmark of lethal prostate cancer. Several mechanisms account for this resistance,…”
Get full text

PKA signaling drives mammary tumorigenesis through Src by Beristain, A G, Molyneux, S D, Joshi, P A, Pomroy, N C, Di Grappa, M A, Chang, M C, Kirschner, L S, Privé, G G, Pujana, M A, Khokha, R

“…Protein kinase A (PKA) hyperactivation causes hereditary endocrine neoplasias; however, its role in sporadic epithelial cancers is unknown. Here, we show that…”
Get full text

1873O - PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors by Pellegrino, B., Llop-Guevara, A., Pedretti, F., Cruz, C., Castroviejo, M., Cedro-Tanda, A., Fasani, R., Mateo, F., Musolino, A., Pujana, M.A., Nuciforo, P.G., Gros, A., Balmana, J., O’Connor, M.J., Serra Elizalde, V.

“…HRR-deficient tumors are sensitive to PARP inhibitors (PARPi) and exhibit high levels of cytosolic DNA that can result in the activation of the STING pathway…”
Get full text

PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors by Pellegrino, B., Llop-Guevara, A., Pedretti, F., Cruz, C., Castroviejo, M., Cedro-Tanda, A., Fasani, R., Mateo, F., Musolino, A., Pujana, M.A., Nuciforo, P.G., Gros, A., Balmana, J., O’Connor, M.J., Serra Elizalde, V.

Get full text

Disease networks identify specific conditions and pleiotropy influencing multimorbidity in the general population by Amell, A., Roso-Llorach, A., Palomero, L., Cuadras, D., Galván-Femenía, I., Serra-Musach, J., Comellas, F., de Cid, R., Pujana, M. A., Violán, C.

“…Multimorbidity is an emerging topic in public health policy because of its increasing prevalence and socio-economic impact. However, the age- and…”
Get full text

Biological reprogramming in acquired resistance to endocrine therapy of breast cancer by Aguilar, H, Solé, X, Bonifaci, N, Serra-Musach, J, Islam, A, López-Bigas, N, Méndez-Pertuz, M, Beijersbergen, R L, Lázaro, C, Urruticoechea, A, Pujana, M A

“…Endocrine therapies targeting the proliferative effect of 17β-estradiol through estrogen receptor α (ERα) are the most effective systemic treatment of…”
Get full text

Germline genetic background contribution to metastatic dissemination in breast cancer extreme phenotype patients by Santonja, A., Pajares, B., Jiménez-Rodríguez, B., Sousa, C. Fernández-De, Ribelles, N., Lluch-Hernandez, A., Catoira, I., Perez-Ruiz, E., Martin, M., Del Monte-Millan, M., Gonzalez-Neira, A., Pita, G., Pujana, M.A., Ruiz, M., Bonifaci, N., De la Haba, J., Sanchez-Rovira, P., Alba, E., Romero, A.

Get full text

Cancer Therapeutic Resistance: Progress and Perspectives (April 7-8, 2016 - Barcelona, Spain) by Hutchinson, E, Pujana, M A, Arribas, J

“…At the Cancer Therapeutic Resistance: Progress and Perspectives conference, in Barcelona, Spain, April 7-8, 2016, researchers, clinicians and students gathered…”
Get full text

149 - Epigenetic mechanisms and therapeutic opportunities in metastatic castration resistant prostate cancer by Ruggero, K., Giacobbe, A., Mitrofanova, A., Calvet, A., Palomero, L., Pujana, M.A., Califano, A., Abate-Shen, C., Aytes, A.

Get full text

HMG20A and HMG20B map to human chromosomes 15q24 and 19p13.3 and constitute a distinct class of HMG-box genes with ubiquitous expression by Sumoy, L, Carim, L, Escarceller, M, Nadal, M, Gratacòs, M, Pujana, M A, Estivill, X, Peral, B

“…The HMG box encodes a conserved DNA binding domain found in many proteins and is involved in the regulation of transcription and chromatin conformation. We…”
Get more information